Pfizer continues to evaluate our approach to non-financial reporting, including adherence to several existing, globally recognized external frameworks. These include the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB) and the International Integrated Reporting Council (IIRC). We have relied on elements of each framework in developing this year's annual review while adhering to none in its entirety. Based on feedback we received in 2015 from a few key stakeholders, we decided to include a GRI Reference Table in this Annual Review as a reference tool to help readers more readily locate relevant information across Pfizer's web-based resources.
We also take into account elements of other Environment, Social and Governance (ESG) indices and sustainability indicators, in particular the Access to Medicines Index and the UN Global Goals (also known as the Sustainable Development Goals).
| GRI Indicator | Description | Reference |
|---|---|---|
| Strategy and Analysis | ||
| G4-1 | CEO/Chair Statement | CEO Letter — To Our Stakeholders |
| Organizational Profile | ||
| G4-3 | Company name |
Pfizer Inc. |
| G4-4 | Company brand, products and services |
CEO Letter — To Our Stakeholders |
| G4-5 | Location of headquarters |
New York, New York (U.S.) |
| G4-6 | Main countries of operation |
Global Commercial Businesses |
| G4-8 | Markets served (e.g. sectors, customers) |
Global Commercial Businesses |
| G4-9 | Scale of company (e.g. employees, sales) |
Performance |
| G4-10 | Employee profile |
Colleagues |
| G4-12 | Description of company supply chain |
Manufacturing and Supply Chain |
| G4-14 | Precautionary approach / principle |
Pfizer manages and reports on our risks and impacts in consideration of the precautionary principle. |
| Identified Material Aspects and Boundaries | ||
| G4-17 | Entities included in financial statements |
About This Review |
| G4-18 | Process for defining report content |
About This Review |
| G4-19 | Material issues / aspects identified |
About This Review |
| G4-23 | Significant changes in scope / boundaries |
Pfizer footprint and capabilities grew with the Hospira acquisition, which was included in the 2015 Annual Review. |
| Stakeholder Engagement | ||
| G4-24 | Stakeholders engaged |
Stakeholder Engagement |
| G4-25 | Basis for identification of stakeholders |
Stakeholder Engagement |
| G4-26 | Approach to stakeholder engagement |
Stakeholder Engagement |
| G4-27 | Issues raised in stakeholder engagement |
Stakeholder Engagement |
| Report Profile | ||
| G4-28 | Reporting period |
About This Review |
| G4-29 | Date of previous report |
See Previous Annual Review |
| G4-30 | Reporting cycle |
About This Review |
| G4-31 | Reporting contact point |
Chris Gray, Senior Director, Corporate Responsibility |
| G4-32 | In accordance option chosen |
GRI Reference Table |
| Governance | ||
| G4-34 | Governance structure |
Governance and Ethics |
| G4-37 | Governance and stakeholder engagement |
Stakeholder Engagement |
| G4-38 | Composition of the Board |
Meet the Pfizer Board of Directors |
| G4-39 | Chair of the Board |
Meet the Pfizer Board of Directors |
| G4-40 | Nomination of Board Members |
The Pfizer Board: Board Policies |
| G4-41 | Conflict of interest and the Board |
The Pfizer Board: Board Policies |
| Ethics and Integrity | ||
| G4-56 | Values, principles and codes |
Pfizer Compliance |
| Economic | ||
| DMA | Disclosures on Management Approach |
The Global Goals |
| G4-EC1 | Direct economic value |
Global Reach: China |
| G4-EC7 | Infrastructure investments and services |
Global Reach: India |
| G4-EC9 | Local supplier spending |
Global Reach: South Africa |
| Environmental | ||
| DMA | Disclosures on Management Approach |
Our Green Journey |
| G4-EN8 | Total water withdrawal by source |
Water Withdrawal
|
| G4-EN23 | Total waste |
Waste Disposed |
| G4-EN27 | Mitigation of product impacts |
Pharmaceuticals in the Environment (PIE) |
| G4-EN32 | Supplier environmental screening |
Manufacturing and Supply Chain |
| G4-EN33 | Supply chain environmental impacts |
Pfizer Issues Supply Chain Environmental Sustainability Goal |
| Social: Labor Practices and Decent Work | ||
| DMA | Disclosures on Management Approach |
Colleagues: OWNIT! Culture |
| G4-LA5 | Health and safety committees |
Employee Health and Safety |
| G4-LA6 | Injuries and work related fatalities |
Colleagues |
| G4-LA9 | Employee training |
Driving Inclusion through Colleague Engagement |
| G4-LA10 | Employee skills and learning |
Colleagues Dare to Tryto Spur Growth |
| Social: Human Rights | ||
| DMA | Disclosures on Management Approach |
Governance and Ethics |
| G4-HR2 | Human rights training |
Colleagues: Unconscious Bias Awareness |
| G4-HR3 | Discrimination |
Colleagues: Inclusion for Individuals with Disabilities and Caregivers |
| Social: Society | ||
| DMA | Disclosures on Management Approach |
Governance and Ethics |
| G4-SO1 | Local community engagement |
Partnering with Youth Advisory Groups |
| G4-SO2 | Impacts on local communities |
Empowering Patients |
| G4-SO3 | Anti-corruption risk |
Practical Ethical Sales and Marketing |
| G4-SO6 | Political contributions |
Corporate and Shareholder Information |
| Social: Product Responsibility | ||
| DMA | Disclosures on Management Approach |
Clinical Trials |
| G4-PR1 | Health and safety impacts of products |
Manufacturing and Supply Chain |
| G4-PR5 | Customer satisfaction |
Access to Medicines |
| G4-PR8 | Customer privacy breaches |
Investigating with Integrity |